In the following video, Motley Fool health-care analyst David Williamson takes a look at Mylan (MYL +0.00%), and its recent agreement to acquire generic injectable products maker Agila Specialties from Strides Arcolab, for $1.6 billion in cash. David tells investors how this deal doubles Mylan's exposure to the high-margin biosimilars market, just as the Affordable Care Act is creating provisions for a pathway to bring biosimilars through an approval process and out to market.
Mylan Just Got More Interesting
By Dave Williamson – Mar 1, 2013 at 5:26PM
NASDAQ: MYL
Mylan
One acquisition that makes this biotech a much tastier investment.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid